SCHEMBL29348785

SCHEMBL29348785

CC(C)(c1ccc(F)cc1)N1CCCCC1=O

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 4/20 0.41
MITF O75030 1/20 0.41
PER2 O15055 2/20 0.40
ALDH1A1 P00352 1/20 0.39
LMNA P02545 1/20 0.39
USP2 O75604 1/20 0.36
CYP2B6 P20813 1/20 0.35
KMT2A Q03164 4/20 0.35
MEN1 O00255 2/20 0.35
MAPT P10636 2/20 0.35
MAPK1 P28482 2/20 0.35
HTT P42858 2/20 0.35
NPC1 O15118 1/20 0.35
XBP1 P17861 1/20 0.35
RAB9A P51151 1/20 0.35
CYP17A1 P05093 1/20 0.35
FKBP1A P62942 1/20 0.34
TDP1 Q9NUW8 1/20 0.34
GLA P06280 1/20 0.34
ALOX5 P09917 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29348754 0.84 HSD11B1 (0.43) SMN1; SMN2MITFALDH1A1USP2CYP2B6
SCHEMBL2697747 0.83 CYP2B6 (0.53) SMN1; SMN2MITFPER2ALDH1A1CYP2B6
SCHEMBL12581558 0.80 TSHR (0.38) SMN1; SMN2MITFALDH1A1LMNAKMT2A
SCHEMBL20476032 0.79 KMT2A (0.39) SMN1; SMN2MITFALDH1A1LMNACYP2B6
SCHEMBL2695770 0.78 CYP2B6 (0.50) SMN1; SMN2MITFPER2ALDH1A1LMNA
SCHEMBL3708789 0.71 CYP2B6 (0.42) SMN1; SMN2ALDH1A1CYP2B6KMT2AMEN1
SCHEMBL122141 0.70 BRD4 (0.41) SMN1; SMN2MITFPER2ALDH1A1LMNA
SCHEMBL868298 0.69 MITF (0.40) SMN1; SMN2MITFPER2ALDH1A1LMNA
SCHEMBL1625501 0.69 MITF (0.40) SMN1; SMN2MITFPER2ALDH1A1LMNA
SCHEMBL16281888 0.69 MITF (0.40) SMN1; SMN2MITFPER2ALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024151547-A1 TARGETED DEGRADATION OF VAV1 MONTE ROSA THERAPEUTICS, INC. (US) 2024-07-18 WO disclosed